|
MPO
|
OGG_3000004353 |
|
|
Middle-stage Alzheimer's Disease (moderate)
|
ADO_0000032 |
[A disease in the middle stage where the dementia symptoms are more pronounced. The person may confuse words, get frustrated or angry, and act in unexpected ways, such as refusing to bathe. Damage to nerve cells in the brain can also make it difficult for the person to express thoughts and perform routine tasks without assistance.] |
|
metal chelation
|
MOP_0000604 |
[The formation of at least two single bonds between a metal atom and a ligand.] |
|
Cholinergic Neurons
|
OMIT_0027570 |
|
|
somatoform disorder
|
DOID_4737 |
[A disease of mental health that involves physical symptoms suggesting a physical illness where the biological or medical cause of the symptoms is indeterminate.] |
|
ependymal cell
|
CL_0000065 |
[A neurectoderm derived cell that lines the neural lumen.] |
|
Alzheimer disease, susceptibility to, mitochondrial
|
MONDO_0010783 |
|
|
amyloid positivity
|
ADO_0000069 |
[A result from clinical assessment that characterizes presence of abnormal amyloid found with cerebrospinal fluid (CSF) and/or positron emission tomography (PET)] |
|
Golgi apparatus
|
GO_0005794 |
[A membrane-bound cytoplasmic organelle of the endomembrane system that further processes the core oligosaccharides (e.g. N-glycans) added to proteins in the endoplasmic reticulum and packages them into membrane-bound vesicles. The Golgi apparatus operates at the intersection of the secretory, lysosomal, and endocytic pathways.] |
|
suvorexant
|
CHEBI_82698 |
[An aromatic amide obtained by formal condensation of the carboxy group of 5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoic acid with the secondary amino group of 5-chloro-2-[(5R)-5-methyl-1,4-diazepan-1-yl]-1,3-benzoxazole. An orexin receptor antagonist used for the management of insomnia.] |
|
MAP2K6
|
OGG_3000005608 |
|
|
MAP2K7
|
OGG_3000005609 |
|
|
MAP2K3
|
OGG_3000005606 |
|
|
polymer
|
CHEBI_60027 |
[A polymer is a mixture, which is composed of macromolecules of different kinds and which may be differentiated by composition, length, degree of branching etc..] |
|
MAP2K1
|
OGG_3000005604 |
|
|
MAPK13
|
OGG_3000005603 |
|
|
NF1
|
OGG_3000004763 |
|
|
GALR1
|
OGG_3000002587 |
|
|
Caspase
|
NCIT_C18153 |
[Caspases are a family of intracellular cysteine proteinases involved in inflammation and apoptosis. These enzymes appear to be involved in the initial signaling events, as well as the downstream proteolytic cleavages, that result in apoptotic cell death. They are specific for aspartic acid at the P1 position and are divided into two classes based on the lengths of their N-terminal pro-domains. Caspases-1, -2, -4, -5, -8, and -10 have long pro-domains; caspases-3, -6, -7, and -9 have short pro-domains. (from Science 1998. 281:1312 and Br Med Bull 1997. 53:478)] |
|
exclusion criterion
|
OBI_0500028 |
[an exclusion criterion (rule) is_a *eligibility criterion* which defines and states a condition which, if met, makes an entity unsuitable for a given task or participation in a given process. For instance, in a study protocol, exclusion criteria indicate the conditions that prospective subjects SHOULD NOT meet to be eligible for participation in a study] |
